Ipsen announced that BYLVAY, Odevixibat capsules (Chinese: 蓓尔唯, 奥德昔巴特胶囊) were officially approved by the National Medical Products Administration of china on December 1 for the treatment of itching in patients with progressive familial intrahepatic cholestasis (PFIC) aged 6 months and older. Previously, under the pilot policy, Odevixibat was implemented in the Hainan Boao Lecheng Medical Technology Pilot Zone.
益普生罕见病治疗药物奥德昔巴特胶囊在华获批
The rare disease treatment drug Odisatbat capsules from Ipsen has been approved in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated